Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

IPN60090

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Ipsen, UT MD Anderson Cancer Center

Drug class:

Glutaminase inhibitor

Related drugs:

‹

pegylated glutaminase/glutamine analog combination (0)

pegylated glutaminase/glutamine analog combination (0)

›

NFE2L2 mutation	Solid Tumor	NFE2L2 mutation	Solid Tumor	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2
KEAP1 mutation	Solid Tumor	KEAP1 mutation	Solid Tumor	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2
NFE2L2 mutation	Lung Cancer	NFE2L2 mutation	Lung Cancer	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2
KEAP1 mutation	Lung Cancer	KEAP1 mutation	Lung Cancer	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2
ASNS underexpression	Solid Tumor	ASNS underexpression	Solid Tumor	IPN60090 Sensitive: C3 – Early Trials IPN60090 Sensitive : C3	IPN60090 Sensitive: C3 – Early Trials IPN60090 Sensitive : C3
ASNS deletion	Ovarian Cancer	ASNS deletion	Ovarian Cancer	IPN60090 Sensitive: C3 – Early Trials IPN60090 Sensitive : C3	IPN60090 Sensitive: C3 – Early Trials IPN60090 Sensitive : C3
NF1 mutation	Leiomyosarcoma	NF1 mutation	Leiomyosarcoma	IPN60090 Sensitive: C4 – Case Studies IPN60090 Sensitive : C4	IPN60090 Sensitive: C4 – Case Studies IPN60090 Sensitive : C4
ASNS underexpression	Ovarian Cancer	ASNS underexpression	Ovarian Cancer	IPN60090 Sensitive: D – Preclinical IPN60090 Sensitive : D	IPN60090 Sensitive: D – Preclinical IPN60090 Sensitive : D